Alvine Initiates Enrollment In Phase 2a Clinical Trial Of ALV003 For Use In The Treatment Of Celiac Disease

Alvine Pharmaceuticals, Inc. announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease. “The commencement of this Phase 2a study is an exciting milestone in the clinical development of ALV003 as a potential therapeutic option for patients with celiac disease,” said Daniel C. Adelman, M.D.

share save 171 16 Alvine Initiates Enrollment In Phase 2a Clinical Trial Of ALV003 For Use In The Treatment Of Celiac Disease

Leave a Reply